Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Nexstim Reaches 208 Completed Treatment Sessions

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Nexstim Reaches 208 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company“) reports clinical outcomes of the 208 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD). Nexstim NBT® system is indicated for the treatment of MDD in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

Treatment outcomes of these 208 patients were very good: 50.5% were in remission at end of treatment and 76.0% had obtained a clinical response.

These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7% and the patient-reported response rates were 41.5-56.4%1. The patient-reported remission and response rates are also higher than those reported in a large >3800 patient series for patients completing clinical rTMS treatment (remission 29.7-36.2%, response 62.7-70.4%)2.

The average patient reported Patient Health Questionnaire (PHQ-9) depression symptom severity score in the Nexstim registry was 20.6 before treatment and decreased to 6.9 by end of treatment. In the >3800 patient series the average PHQ-9 score before treatment was reported to be 19.8 and to have decreased to 11.1 by end of treatment2. The range of PHQ-9 is from 0 to 27 with higher scores indicating more severe symptoms. The scores correspond to disease severity as follows: 0-4 = none to minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, 20-27 = severe depression.

The clinical outcomes of majority of the patients treated with SmartFocus® rTMS in the United States are being collected in a registry — the anonymous information is provided by participating clinical sites using Nexstim’s SmartFocus® technology.

According to the registry, the average general impression of receiving SmartFocus® rTMS treatment reported by the patients having completed the treatment was very positive with a mean score of 9.27 on a scale from 0 to 10 (10 = best possible).

Mikko Karvinen, CEO of Nexstim, said: “We are very happy to have reached one of our year 2021 key strategic objectives of over 200 completed treatment sessions of depression patients in our patient data registry. This registry continues to provide us with more promising data on the outcomes of Nexstim SmartFocus® rTMS treatments with our Nexstim NBT® System. We are especially proud of the fast progress considering the challenging circumstances caused by the COVID-19 pandemic. These treatment results support our continued work in bringing Nexstim technology available for as many patients as possible.”

1) Carpenter L. et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jul;29(7):587-96. Epub 2012 Jun 11.

2) Sackheim, H. et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. Journal of Affective Disorders 277 (2020) 65–74.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine